



Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

September 6, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 6, 2022-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.

The on-demand webcast of the presentation may be accessed in the [Investors](#) section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for two weeks following the presentation.

About Concert

[Concert Pharmaceuticals](#) is a late-stage clinical biopharmaceutical company that is developing [CTP-543](#), a novel oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with CTP-543 in adults with alopecia areata, a serious autoimmune dermatological condition. The Company is also evaluating the use of CTP-543 in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20220906005117/en/>

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Source: Concert Pharmaceuticals, Inc.